Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
2022 · Cancer Immunology Immunotherapy · 30 citations
https://doi.org/10.1007/s00262-022-03151-2
T
Thomas Sheffield
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
32
Papers
604
Citations
12
h-index
14
i10-index
Thomas Sheffield is an academic researcher from Sandia National Laboratories California. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Gene expression and cancer classification & Immune Cell Function and Interaction. The author has an h-index of 12, co-authored 28 publications.
ORCID: 0000-0001-9073-6334Papers by this author
worksNanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies
2025 · PLoS Pathogens · 2 citations
https://doi.org/10.1371/journal.ppat.1012903
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
2023 · Translational Oncology · 1 citations
https://doi.org/10.1016/j.tranon.2023.101689
Integrative multi-omic and phenotypic analysis of open raceway pond production of Monoraphidium minutum 26B-AM reveals distinct stress signatures for scale-up and infection
2026 · Biotechnology for Biofuels and Bioproducts · 0 citations
https://doi.org/10.1186/s13068-025-02730-6
Iterative ML and Experiments for Emerging VOCs
2026 · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · 0 citations
https://doi.org/10.11578/dc.20260211.2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat